The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Oct 2018 13:58

RNS Number : 5611C
GlaxoSmithKline PLC
01 October 2018
 

GlaxoSmithKline plc

 

Total Voting Rights and Capital

 

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 30 September 2018 consisted of 5,375,085,545 shares of 25 pence each ('Ordinary Shares'), of which 414,605,950 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 4,960,479,595. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

 

V A Whyte

Company Secretary

 

1 October 2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUGGMAUUPRGPG
Date   Source Headline
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
6th Jun 20227:00 amRNSUS FDA approval of Priorix
1st Jun 20224:55 pmRNSTotal Voting Rights
1st Jun 20221:00 pmRNSDemerger update: Publication of Documents
1st Jun 20227:00 amRNSDemerger update: Submission of Documents to FCA
31st May 20227:00 amRNSGSK to acquire Affinivax, Inc.
30th May 202210:00 amRNSFurther appointments to Designate Haleon Board
27th May 20227:00 amRNSGSK Cervarix two-dose schedule approved by NMPA
25th May 20223:41 pmPRNDirector/PDMR Shareholding
23rd May 20223:21 pmRNSDirector/PDMR Shareholding
19th May 202210:02 amRNSIain Mackay - External Appointment
16th May 20222:00 pmRNSChange of name to GSK plc
13th May 20225:13 pmRNSDirector/PDMR Shareholding
12th May 20228:58 amRNSDirector/PDMR Shareholding
11th May 20225:17 pmRNSBlock listing Interim Review
9th May 20222:53 pmRNSDirector/PDMR Shareholding
4th May 20225:49 pmRNSResult of AGM
4th May 202210:00 amRNSDirectorate Change
3rd May 20224:52 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNS1st Quarter Results
26th Apr 20229:32 amRNSDirector/PDMR Shareholding
19th Apr 20227:00 amRNSDaprodustat application accepted for review by FDA
14th Apr 20222:23 pmRNSDirector/PDMR Shareholding
14th Apr 20222:15 pmRNSDirector/PDMR Shareholding
14th Apr 20221:29 pmRNSDirector/PDMR Shareholding
13th Apr 20225:11 pmRNSDirector/PDMR Shareholding
13th Apr 20229:32 amRNSDirector/PDMR Shareholding
13th Apr 20227:00 amRNSGSK agrees to acquire Sierra Oncology for $1.9bn
12th Apr 20225:10 pmRNSDirector/PDMR Shareholding
12th Apr 20224:23 pmRNSDirector/PDMR Shareholding
12th Apr 20224:00 pmRNSDirector/PDMR Shareholding
12th Apr 20223:48 pmRNSDirector/PDMR Shareholding
1st Apr 20224:03 pmRNSTotal Voting Rights
1st Apr 202211:20 amRNSGSK - segment and product sales reporting changes
28th Mar 20221:00 pmRNSPublication of 2022 AGM Notice
24th Mar 20223:22 pmRNSDirector/PDMR Shareholding
24th Mar 20222:00 pmRNSFDA update: Cabenuva oral lead-in now optional
23rd Mar 20225:03 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSIssuance of Notes
16th Mar 20222:40 pmRNSDirector/PDMR Shareholding
15th Mar 20222:45 pmRNSDirector/PDMR Shareholding
15th Mar 202210:00 amRNSAppointments to Designate Haleon Board
11th Mar 20222:55 pmRNSDirector/PDMR Shareholding
9th Mar 20221:44 pmRNSDirector/PDMR Shareholding
8th Mar 20226:24 pmRNSGSK Annual Report 2021 on Form 20-F
4th Mar 202211:03 amRNSGSK publishes Annual Report 2021
1st Mar 20222:30 pmRNSTotal Voting Rights
1st Mar 20221:18 pmRNSDirector/PDMR Shareholding
1st Mar 20229:55 amRNSDirector/PDMR Shareholding
1st Mar 20227:00 amRNSDaprodustat application accepted for review by EMA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.